➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Harvard Business School
Johnson and Johnson
McKinsey
Merck

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Telavancin hydrochloride - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic sources for telavancin hydrochloride and what is the scope of patent protection?

Telavancin hydrochloride is the generic ingredient in one branded drug marketed by Cumberland Pharms and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Telavancin hydrochloride has one hundred and twenty-eight patent family members in thirty-five countries.

One supplier is listed for this compound.

Summary for telavancin hydrochloride
International Patents:128
US Patents:11
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 5
Clinical Trials: 15
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in telavancin hydrochloride?telavancin hydrochloride excipients list
DailyMed Link:telavancin hydrochloride at DailyMed
Recent Clinical Trials for telavancin hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Joseph KutiPhase 4
Theravance Biopharma, US, Inc.Phase 4
University of Illinois at ChicagoPhase 1

See all telavancin hydrochloride clinical trials

Pharmacology for telavancin hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for telavancin hydrochloride

US Patents and Regulatory Information for telavancin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-001 Sep 11, 2009 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-002 Sep 11, 2009 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-002 Sep 11, 2009 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-001 Sep 11, 2009 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-002 Sep 11, 2009 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-002 Sep 11, 2009 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for telavancin hydrochloride

International Patents for telavancin hydrochloride

Country Patent Number Estimated Expiration
European Patent Office 1292612 ⤷  Free Forever Trial
China 100532392 ⤷  Free Forever Trial
Australia 2001261107 ⤷  Free Forever Trial
Slovakia 287470 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 2005042568 ⤷  Free Forever Trial
Czech Republic 303672 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for telavancin hydrochloride

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1292612 11C0051 France ⤷  Free Forever Trial PRODUCT NAME: TELAVANCINE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
1292612 132012902025885 Italy ⤷  Free Forever Trial PRODUCT NAME: TELAVANCINA(VIBATIV); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/705/001-002, 20110902
1292612 C300507 Netherlands ⤷  Free Forever Trial PRODUCT NAME: TELAVANCINE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, INCLUSIEF TELAVANCINE HYDROCLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001 - 002 20110902
1292612 C 2012 002 Romania ⤷  Free Forever Trial PRODUCT NAME: TELAVANCIN SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIAINCLUZAND CLORHIDRAT DE TELAVANCIN; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/705/001, RO EU/1/11/705/002; DATE OF NATIONAL AUTHORISATION: 20110902; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/705/001, EU/1/11/705/002; DATE OF FIRST AUTHORISATION IN EEA: 20110902
1292612 PA2012002,C1292612 Lithuania ⤷  Free Forever Trial PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902
1292612 36/2011 Austria ⤷  Free Forever Trial PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ HIEVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Harvard Business School
Johnson and Johnson
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.